Vaxcyte (PCVX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Vaxcyte (PCVX) is Neutral.

The composite score behind that read is +0.01, weighing +0.27 of bullish evidence against -0.31 bearish.

Vaxcyte last closed at $71.38, +9.78% on the session.

Against the IVW growth benchmark the position is +8.98% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

12 graded predictions for PCVX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Vaxcyte in the 21st percentile on return on equity, where 100 is best.

Vaxcyte is classified under Health Care / Biotechnology, with a market capitalisation of $9.67B.

StockMap tracks Vaxcyte as the 28th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Vaxcyte ranks 90th of 381 in the group, against a group median of -0.08.